STAT Plus: CRISPR scientists are in for the long haul. Wall Street is less patient

Collectively, CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA) lost nearly $500 million in value in a single day.

More From BioPortfolio on "STAT Plus: CRISPR scientists are in for the long haul. Wall Street is less patient"